Patents by Inventor Michael A. Barry

Michael A. Barry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12258572
    Abstract: This document provides adenovirus vectors and methods and materials related to using adenovirus vectors. For example, adenoviruses for delivering nucleic acid encoding one or more immunogens (e.g., one or more immunogens associated with a pathogen causing an infection) to cells within a mammal such that the mammal produces an effective immune response against the immunogen(s) are provided.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: March 25, 2025
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Michael A. Barry
  • Publication number: 20250027058
    Abstract: This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventor: Michael A. BARRY
  • Patent number: 12139726
    Abstract: This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: November 12, 2024
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventor: Michael A. Barry
  • Publication number: 20240325570
    Abstract: This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of developing, a polycystic disease (e.g., a polycystic kidney disease (PKD)). For example, methods and materials that can be used to increase a level of polycystin-1 (PC-1) polypeptides and/or polycystin-2 (PC-2) polypeptides within a mammal having, or at risk of developing, a polycystic disease) are provided. In some cases, nucleic acid designed to increase a level of PC-1 polypeptides and/or PC-2 polypeptides within a mammal can be administered to a mammal having, or at risk of developing, a polycystic disease to treat the mammal.
    Type: Application
    Filed: January 14, 2022
    Publication date: October 3, 2024
    Inventors: Michael A. Barry, Christopher Y. Chen, Jeffrey D. Rubin, Vincente E. Torres
  • Patent number: 12060582
    Abstract: This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: August 13, 2024
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventor: Michael A. Barry
  • Publication number: 20240175050
    Abstract: Methods and materials for treating propionic acidemia are provided herein. For example, methods and materials for using AAVs to express a PCCA polypeptide and/or a PCCB polypeptide within a mammal to treat propionic acidemia are provided.
    Type: Application
    Filed: March 18, 2022
    Publication date: May 30, 2024
    Inventor: Michael A. Barry
  • Publication number: 20240026307
    Abstract: This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 25, 2024
    Inventor: Michael A. BARRY
  • Publication number: 20240018546
    Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
    Type: Application
    Filed: September 15, 2023
    Publication date: January 18, 2024
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Michael A. Barry, Eric Weaver
  • Publication number: 20230365943
    Abstract: This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.
    Type: Application
    Filed: July 18, 2023
    Publication date: November 16, 2023
    Inventor: Michael A. BARRY
  • Patent number: 11795477
    Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: October 24, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Michael A. Barry, Eric Weaver
  • Publication number: 20230279428
    Abstract: This document provides adenovirus vectors and methods and materials related to using adenovirus vectors. For example, adenoviruses for delivering nucleic acid encoding one or more immunogens (e.g., one or more immunogens associated with a pathogen causing an infection) to cells within a mammal such that the mammal produces an effective immune response against the immunogen(s) are provided.
    Type: Application
    Filed: August 17, 2021
    Publication date: September 7, 2023
    Inventor: Michael A. Barry
  • Patent number: 11746334
    Abstract: This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: September 5, 2023
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventor: Michael A. Barry
  • Patent number: 11485767
    Abstract: This invention provides methods and materials for treating cancer. The invention encompasses methods and materials for delivering programmed death-ligand 1 (PD-L1) binding compounds and/or compositions containing one or more monovalent or multivalent programmed death-ligand 1 (PD-L1) binding compounds which are administered to a mammal having cancer to treat the mammal. In some cases, a multivalent PD-L1 binding compound can include two or more programmed cell death protein 1 (PD-1) polypeptides (and/or fragments thereof having the ability to bind PD-L1). This invention also provides methods and materials for making multivalent PD-L1 binding compounds and methods and materials for making nucleic acid molecules that encode PD-L1 binding compounds.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: November 1, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventor: Michael A. Barry
  • Publication number: 20220170046
    Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 2, 2022
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Michael A. Barry, Eric Weaver
  • Patent number: 11279953
    Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: March 22, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Michael A. Barry, Eric Weaver
  • Publication number: 20220049271
    Abstract: This document provides adenovirus vectors and methods and materials related to using adenovirus vectors. For example, adenoviruses for delivering nucleic acid encoding one or more immunogens (e.g., one or more immunogens associated with a pathogen causing an infection) to cells within a mammal such that the mammal produces an effective immune response against the immunogen(s) are provided.
    Type: Application
    Filed: September 8, 2021
    Publication date: February 17, 2022
    Inventor: Michael A. Barry
  • Publication number: 20210355453
    Abstract: This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.
    Type: Application
    Filed: June 14, 2021
    Publication date: November 18, 2021
    Inventor: Michael A. BARRY
  • Patent number: 11149286
    Abstract: This document provides adenovirus vectors and methods and materials related to using adenovirus vectors. For example, adenoviruses for delivering nucleic acid encoding one or more immunogens (e.g., one or more immunogens associated with a pathogen causing an infection) to cells within a mammal such that the mammal produces an effective immune response against the immunogen(s) are provided.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: October 19, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Michael A. Barry
  • Publication number: 20200339654
    Abstract: This invention provides methods and materials for treating cancer. The invention encompasses methods and materials for delivering programmed death-ligand 1 (PD-L1) binding compounds and/or compositions containing one or more monovalent or multivalent programmed death-ligand 1 (PD-L1) binding compounds which are administered to a mammal having cancer to treat the mammal. In some cases, a multivalent PD-L1 binding compound can include two or more programmed cell death protein 1 (PD-1) polypeptides (and/or fragments thereof having the ability to bind PD-L1). This invention also provides methods and materials for making multivalent PD-L1 binding compounds and methods and materials for making nucleic acid molecules that encode PD-L1 binding compounds.
    Type: Application
    Filed: April 28, 2020
    Publication date: October 29, 2020
    Inventor: Michael A. BARRY
  • Publication number: 20200255865
    Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Michael A. Barry, Eric Weaver